<i>Mycoplasma genitalium</i> Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand

Abstract

M anagement of Mycoplasma genitalium infections is challenging because the limited treatment options have been affected by rapidly evolving resistance to antimicrobial drugs. Molecular approaches are the preferred method of M. genitalium detection, and resistance is determined genotypically. 23S rRNA mutations are associated with macrolide resistance and azithromycin treatment failures (1-3), whereas fluoroquinolone resistance is associated with mutations in the quinolone resistance-determining region, specifically in the gyrA and parC genes (4).